Note: Ingredients listed on restricted chemical lists
EC/CAS
232-674-9/9004-34-6
Name of the chemical
cellulose
Concentration
N/A
EC/CAS
201-069-1/77-92-9
Name of the chemical
Citric acid
Concentration
N/A
EC/CAS
209-150-3
Name of the chemical
Aluminium, zinc, magnesium and calcium stearates
Concentration
N/A
General Information
Revision date
2018-08-28
Product name
Cabergoline Tablets, USP
1.2.1 Relevant identified uses
Used for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary
Emergency telephone
1-866-321-5031
Icons in SDS
Company Information
company name
Ingenus Pharmaceuticals, LLC
e-mail address of the competent person responsible for the Safety Data Sheet
customerservice@ingenus.com
Section 2
SECTION 2: Hazards identification
Appearance: White to off-white tablets
Hazard statements
Non-hazardous in accordance with international standards for workplace safety.
Additional information
Short Term: Active ingredient may be harmful if swallowed. (based on animal data). Accidental ingestion may cause effects similar to those seen in clinical use. Known Clinical Effects: Ingestion of this material may cause effects similar to those seen in clinical use including nausea, vomiting, abdominal cramps, anorexia, diarrhea, and constipation. This drug may decrease the quantity/quality of breast milk. EU Indication of danger: Not classified. Australian Hazard Classification Non-Hazardous Substance. Non-Dangerous Goods. (NOHSC): Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.
